Indoco Remedies Ltd has received European Union Good Manufacturing Practice (EU GMP) certification for its solid oral dosage manufacturing facility at Baddi, Himachal Pradesh, following a successful inspection by the Malta Medicines Authority. The inspection was conducted between January 29 and February 3, 2026, at the company’s Unit I facility, which manufactures solid oral dosage formulations for domestic and international markets. The certification confirms that the facility complies with the Good Manufacturing Practice requirements outlined under European regulatory guidelines and strengthens Indoco’s position in regulated global pharmaceutical markets.
The approval is expected to further support the company’s international business expansion strategy and reinforce its commitment to maintaining globally benchmarked manufacturing and quality standards across its operations. Commenting on the development, Aditi Panandikar, Managing Director of Indoco Remedies Ltd, said the certification reflects the company’s continued focus on quality, compliance and adherence to international regulatory requirements. She added that Indoco remains committed to delivering high-quality pharmaceutical products to patients and healthcare partners across India and overseas markets.
Indoco Remedies is a research-driven pharmaceutical company with a broad portfolio spanning finished dosage formulations and active pharmaceutical ingredients. The company operates ten manufacturing facilities, including six facilities dedicated to finished dosage formulations and four API manufacturing units, supported by a modern research and development centre and a contract research organisation facility.
Its manufacturing sites have received approvals from several global regulatory authorities, including the US Food and Drug Administration and the UK Medicines and Healthcare products Regulatory Agency. The latest certification from the Malta Medicines Authority further strengthens the company’s standing in Europe and regulated export markets.
Indoco has established a strong presence in India through multiple therapeutic segments including gastroenterology, respiratory care, anti-infectives, ophthalmology, cardiovascular therapies, diabetes care, nutritionals, pain management and women’s health. The company’s products generate more than 109 million prescriptions annually from healthcare professionals across multiple specialties. The company also maintains strategic partnerships and supply arrangements with leading global generic pharmaceutical companies, supporting its international business operations and market expansion initiatives.
With a workforce of more than 6,000 employees, including over 300 scientists and technical professionals, Indoco continues to focus on product development, manufacturing excellence and research-driven growth. The company has consistently invested in strengthening quality systems, process optimisation and compliance infrastructure to meet the evolving requirements of regulated healthcare markets.
The successful EU GMP certification comes at a time when pharmaceutical companies are increasingly focusing on strengthening supply chain reliability, manufacturing quality and regulatory compliance across global operations. For Indoco Remedies, the approval represents another milestone in its efforts to expand international market access while maintaining high standards of product safety, quality and operational excellence.
